Page 11234..10..»

Archive for the ‘Nano medicine’ Category

Nanotech opens up job options in variety of industries – BL on Campus

Tuesday, August 17th, 2021

The word nano refers to the length scale (one nanometre is one-billionth of a metre) that is one thousand times smaller than the micro scale, the scale that was traditionally associated with the electronics industry. Viruses and DNA are examples of natural objects on the nano scale; in contrast a human cell can appear enormous.

The term nanotechnology refers to the engineering, measurement and understanding of nano-scaled materials and devices. Manipulating matter atom by atom and creating features on the atomic or nano scale is now a proven technology and there is an ever growing catalogue that utilises nanotechnology.

Nanotechnology represents an entire scientific and engineering field, broadly within Materials Science and Engineering, and not just a single product or even group of products. As a consequence of this there are several different types of nanotechnology, and many applications associated with each type. There are also several other types of nano-sized objects which exist in our environment, both natural and unnatural such as films and coatings, embedded nanotechnology, biologically natural, biological nanotechnology, natural particles, manufactured particles, nano-electrical mechanical systems.

Building on current nanotechnology-enabled applications in areas as diverse as consumer electronics, medicine, energy, water purification, aerospace, automotive, infrastructure, sporting goods, textiles, and agriculture, the nanotechnology research underway today will enable entirely new capabilities and products. Nanotechnology also underpins key industries of the future. For example, new architecture and paradigms exploiting nanotechnology are providing the foundation for artificial intelligence (AI), quantum information science (QIS), next-generation wireless communications, and advanced manufacturing.

While advances in modern electronics have long been at the nanoscale, new nanomaterials and designs will ensure the continued strength of the semiconductor industry, which powers computing, e-commerce, and national security. Nanotechnology also enables the rapid genomic sequencing and sensing required to advance medicine and biotechnology. Nanotechnology R&D has enabled early detection of emerging diseases and will lead to the treatments of the future. Past investments in nanotechnology research and development have provided a foundation to support the response to the Covid-19 pandemic. Nanotechnology-enabled applications include vaccines, sensors, masks, filters, and antimicrobial coatings.

Examples of nanotechnology innovations are: a highly sensitive wearable gas sensor; nanoparticles absorbed by plants to deliver nutrients; durable, conductive yarns made with MXene; electrodes that incorporate nanoparticles and enable the conversion of sunlight to hydrogen fuel; nano-engineered pores in a membrane for water filtration; drug-loaded nano particles carried by red blood cells; and the first programmable memristor computer, enabling low-power AI applications. Nanotechnology advances are impacting a variety of other sectors including consumer electronics, aerospace, automotive, infrastructure, sporting goods, and agriculture.

Research Infrastructure

The research infrastructure, including physical and cyber resources as well as education and workforce development efforts, is critical to support the entire funding ecosystem (National Nanotechnology Initiative), and agencies will continue to invest in these important areas. Agencies use a wide variety of mechanisms to support the research infrastructure, including Centre grants, instrumentation development or acquisition programmes, training grants, fellowships, and collaborative programmes that support workforce development.

Career opportunities

The scope and application of nanotechnology is tremendous. Indian engineering and science graduates are increasingly opting for nanotechnology. Right from medicine, pharmaceuticals, information technology, electronic, opto-electronics, energy, chemicals, advanced materials to textiles, nanotechnology has its applications. Nanotechnology provides job opportunities in health industry; pharmaceutical industry; agriculture industry; environment industry; food and beverage industry as well in government and private research institutes.

Skills

One needs to have a diehard passion for research, especially to find out new structures in the field of nanotechnology. It is important to have sound analytical skills, along with a scientific bent of mind. Analysing and interpreting skills are a necessity in this field and also to accept failures in experiments as a challenge. Other necessary skills which are required are: Good mathematical and computer programming skills; adequate laboratory training for expert handling of advanced equipment; ability to learn and adopt new techniques; have a systematic way of working; a natural propensity for research work; keep track of the latest scientific news, books and research magazines; a good background of physics, chemistry, medicine, electronics and biotechnology

Job Prospects

A lot of job opportunities and a research career exists in the areas of nano-device, nano-packaging, nano-wires, nano-tools, nano-biotechnology, nano-crystalline materials, nano-photonics and nano-porous materials to name a few. It is estimated that around three million nanotechnology skilled workforce will be required worldwide by 2021. Many government institutes and Indian industries have focused on nano-materials. It is also estimated nano-technology will create another five million jobs worldwide in support fields and industries. A professional in the field of nanotechnology can easily find lucrative jobs in most of fields.

Since nanotechnology is a special branch that essentially combines physics, chemistry, biology, engineering and technology, it is opening up job prospects for students specialising in these subjects. The career opportunities in the fields of nanoscale science and technology are expanding rapidly, as these fields have increasing impact on many aspects of our daily lives.

A professional in the field of nanotechnology can easily find viable career opportunities in various sectors. They can work in the field of nano-medicine, bio-informatics, stem cell development, pharmaceutical companies, and nano toxicology and nano power generating sectors.

The major areas for the development of applications involving nanotechnology are medical and pharmaceuticals, information technology, electronics, magnetics and opto-electronics, energy chemicals, advanced materials and textiles.

Nanotechnology has varied applications in drug delivery to treat cancer tumours (without using radiotherapy and chemotherapy), solar energy, batteries, display technologies, opto-electronic devices, semiconductor devices, biosensors, luminous paints, and many others. A major challenge in this emerging field is the training for a new generation of skilled professionals.

An abundance of job opportunities awaits candidates with an MTech in Nanotechnology from India and abroad. Indian industry has focused on nanomaterials and many scientific institutions have started research and development activities in the field. The CSIR has set up 38 laboratories, across the country, to carry out research and development work in this field. Those with a PhD in Nanotechnology will have vibrant opportunities in the R&D sectors.

It is a perfect career for those who have a scientific bent of mind and a passion for studying and experimenting with the minutest molecules. Students with a science and engineering background and even mathematics with a physics background can pursue Nanotechnology as a career. Candidates with MTech in Nanotechnology are in great demand both in India and abroad.

(The writer is Associate Professor, Department of Physics and Nanotechnology, SRM University)

Read this article:
Nanotech opens up job options in variety of industries - BL on Campus

Read More...

Homeopathic remedies that cattle farmers can use – Thats Farming

Tuesday, August 17th, 2021

Dr Chris Aukland BVSc VetMFHom MRCVS, Head of Livestock Health Programmes, Whole Health Agriculture, discusses homeopathy.

Chris leads the farmer education and support team at Whole Health Agriculture (WHAg). They offer training and support to help farmers develop skills to create resilient natural health and longevity in their livestock.

Chris has over 30 years experience in holistic veterinary practice and combines his work at WHAg with small animal surgery, ensuring he keeps up with the latest advances in alternative and conventional veterinary practice.

Dr CA: Homeopathy is an established system of medicine that supports the individuals own healing process, stimulating a state of dynamic homeostasis (or optimum balance), thereby minimising susceptibility to disease and fostering good health.

Homeopathy works by reminding the bodys natural healing mechanisms of what needs to be done to get back into a state of balance.

Often termed nano-medicine, homeopathy uses ultra-dilute substances to individualise treatment.

The symptoms presented by a sick animal or person are matched to the symptom picture of various remedies, choosing the remedy which is the closest match.

For example, caffeine can make us more alert. However, too much caffeine in some people can provoke sleeplessness, restlessness, anxiety and inability to focus.

Working on the homeopathic principle of treating like-with-like for somebody experiencing these symptoms perhaps due to worry or stress.

The best match might be the homeopathic remedy Coffea (produced from coffee), which has a symptom picture of sleeplessness, anxiety, restlessness and an inability to focus.

We have seen increasing demand for training and ongoing support from farmers, particularly over the last five years.

Our training webinars sell out. We are close to launching a membership and online learning platform developed to meet needs and support farmers no matter where they are in the world.

There appears to have been a quiet underground movement for some years. Suddenly, it is becoming more mainstream. Interest has always spread through word of mouth farmers trust farmers; if they say something is working, it creates demand.

A question to which we also wanted to know the answer!

We recently conducted a survey into the use of CAM (Complementary & Alternative Methods /Products/Medicines) among farmers to find out what they were using and why.

221 farmers, mainly from UK and Ireland, responded, the majority, 88%, of which used homeopathy. We looked at (among other things) specific markers based on figures that farmers are required to record.

Of all farmers who responded, 66% reported lower vet and medicine costs, and 65% responded that their use of CAMs has resulted in or contributed to zero, low or reduced antibiotic usage.

40% reported zero, low or reduced wormer usage and 36% reported reduced frequency or severity of lameness. One third reported increased financial profitability of the farm.

Of the 70 commercial dairy farmers who responded:

Also highly noteworthy is that 69% of dairy farmers reported fewer cases of milk withdrawal, and over half noted less frequent/severe mastitis and lower cell counts.

52% of dairy farmers have seen increased financial profitability of the farm.

Homeopathy is particularly useful because there is no risk of:a) Toxic side-effects,b) Drug residues, so no withdrawal period,c) Can help farmers reduce reliance on antibiotics

It can mitigate stress in routine events where conventional veterinary options have little to offer; events that we take for granted, such as weaning, tail ringing, castration, routine examination, separation etc. which can result in loss of condition or production.

A sick animal is an expensive animal. It can also improve herd vitality so that they are more resistant to infectious disease, parasites, etc. and animals thrive better.

Farmers also use homeopathy for infections. The following slide is taken from our survey and shows responses to the question: What conditions have you treated successfully without antibiotics? The dark blue bar shows the responses for homeopathy.

NB: The use of homeopathy should NEVER replace the vet. Our advice is always based on a holistic traffic-light triage. For any problem:

Look at the RED level first and for any serious condition, contact your vet as usual.

Then look at the GREEN level; this is your husbandry level. Can you mitigate any potential maintaining causes such as draughty barns, a change in feed, stress to the animal?

Finally, you can address the AMBER level and look at homeopathic and other natural medicine options.

In the UK, it is illegal to treat TB, which is a notifiable disease. As such, homeopathy should never be used to treat TB.

Always be aware of the local regulations. For any farm, we want all livestock to be as healthy and naturally resilient as possible.

Used well, homeopathy can improve the overall health of the farm, which will mean the farmer experiences less disease generally. A healthier, more vibrant cow is much less likely to be susceptible to TB.

Homeopathy has the potential, applied correctly, to not only treat symptoms but also to increase resilience and reduce susceptibility to disease.

TF: What should they take into account before they do so?

Seek advice and support. Do your research. Speak to other farmers using it with good results about how they integrate it into their health planning.

It is important also to get appropriate veterinary support. Contact the Irish Society of Veterinary Homeopaths.

In the UK, there are no restrictions on farmers sourcing and using remedies in the UK. There are various useful remedy kits available. In Ireland, remedies must be sourced via a homeopathic vet.

There are hundreds of homeopathic remedies but some key ones that farmers use all the time are:

Farmers tend to use liquid remedies and spray bottles for ease of administration to individuals/groups or put remedies into the troughs if dosing the whole herd/flock.

This is difficult to quantify as every farm is different, and one farm may measure success by a different set of criteria than others.

However, our survey showed that 66% of farmers/71% of dairy farmers reported lower vet and medicine costs.

Sally Wood, who is a conventional turned organic farmer in Wales, told us:

I think the mainstream assumption is always that if you use homeopathy to reduce antibiotics, your welfare will go down and your cull rate will go up, but ours proved the opposite, and our herd is so healthy that we can sell our surplus stock.

When people ask me whether homeopathy works, I tell them that our vet and med bill has halved.

Interest appears to be growing. A group of homeopathic vets and farmers have done training together via NOTS, who all support one another in their learning.

Pat Ahernes Homeopathic Dairy Farm on Facebook is great for insight into how it can be used on the farm.

Anyone can start with a few simple remedies. (Obviously, farmers need to observe the regulations in their country and stay legal!)

We know some farmers who ONLY use the remedies Aconite and Arnica and report success.

Training and support are important for best results and to transform the health of a herd/flock. This is something that WHAg is dedicated to providing, including piloting a scheme to train farmers to provide coaching to other farmers.

This is not to replace the vet but to help them integrate strategies to foster health and resilience.

I think it is inevitable. People generally are taking a more holistic view on health.

Overall, we are more planet conscious. Furthermore, farmers are exploring less toxic health options such as fermented foods, herbs and homeopathy.

Also, Antimicrobial Resistance (AMR) is not going away; farmers are under a lot of pressure to reduce antibiotics.

In the UK, we see buyers and supermarkets leading the trend for reduction in antibiotics, and some organic milk buyers expect members to achieve PWAB status (Produced Without Antibiotics).

In conclusion, homeopathy and other non-toxic inputs such as ferments, herbs etc., offer a viable alternative for farmers.

For more information on WHAgs new learning and membership platform, and to sign up to our newsletter: see http://www.wholehealthag.org

See Facebook The Farmacy at WHAg

To share your story with Thats Farming, email catherina@thatsfarming.com

View original post here:
Homeopathic remedies that cattle farmers can use - Thats Farming

Read More...

Healthcare Nanotechnology (Nanomedicine) Market Trend, Technology Innovations and Growth Prediction 2021-2027 The Manomet Current – The Manomet…

Tuesday, August 17th, 2021

The research analysis of Healthcare Nanotechnology (Nanomedicine) market offers significant information regarding the major trends that define this business landscape with regards to the regional outlook and competitive scenario. The report also highlights the limitations & challenges that could hamper the industry remuneration alongside the key opportunities that will aid in business expansion. Moreover, the document provides crucial insights regarding the effect of COVID-19 pandemic on the overall market outlook.

This report contains market size and forecasts of Healthcare Nanotechnology (Nanomedicine) in Global, including the following market information:Global Healthcare Nanotechnology (Nanomedicine) Market Revenue, 2016-2021, 2022-2027, ($ millions)Global top five companies in 2020 (%)

The global Healthcare Nanotechnology (Nanomedicine) market was valued at 200560 million in 2020 and is projected to reach US$ 285060 million by 2027, at a CAGR of 9.2% during the forecast period.Research has surveyed the Healthcare Nanotechnology (Nanomedicine) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Download PDF Sample of Healthcare Nanotechnology (Nanomedicine) Market report @ https://www.themarketinsights.com/request-sample/253870

Total Market by Segment:Global Healthcare Nanotechnology (Nanomedicine) Market, By Type, 2016-2021, 2022-2027 ($ millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Type, 2020 (%)NanomedicineNano Medical DevicesNano DiagnosisOther

China Healthcare Nanotechnology (Nanomedicine) Market, By Application, 2016-2021, 2022-2027 ($ millions)China Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Application, 2020 (%)AnticancerCNS ProductAnti-infectiveOther

Global Healthcare Nanotechnology (Nanomedicine) Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)Global Healthcare Nanotechnology (Nanomedicine) Market Segment Percentages, By Region and Country, 2020 (%)North AmericaUSCanadaMexicoEuropeGermanyFranceU.K.ItalyRussiaNordic CountriesBeneluxRest of EuropeAsiaChinaJapanSouth KoreaSoutheast AsiaIndiaRest of AsiaSouth AmericaBrazilArgentinaRest of South AmericaMiddle East & AfricaTurkeyIsraelSaudi ArabiaUAERest of Middle East & Africa

Report Customization available as per requirements Request Customization@ https://www.themarketinsights.com/request-customization/253870

Competitor AnalysisThe report also provides analysis of leading market participants including:Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)Total Healthcare Nanotechnology (Nanomedicine) Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:AmgenTeva PharmaceuticalsAbbottUCBRocheCelgeneSanofiMerck & CoBiogenStrykerGilead SciencesPfizer3M CompanyJohnson & JohnsonSmitH& NephewLeadiant BiosciencesKyowa Hakko KirinTakedaIpsenEndo International

To Check Discount @ https://www.themarketinsights.com/check-discount/253870

Table of ContentChapter One: Introduction to Research & Analysis Reports

Chapter Two: Global Healthcare Nanotechnology (Nanomedicine) Overall Market Size

Chapter Three: Company Landscape

Chapter Four: Market Sights by Product

Chapter Five: Sights by Application

Chapter Six: Sights by Region

Chapter Seven: Players Profiles

Chapter Eight: Conclusion

Chapter Nine: Appendix9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Table and FigureTable 1. Healthcare Nanotechnology (Nanomedicine) Market Opportunities & Trends in Global Market

Table 2. Healthcare Nanotechnology (Nanomedicine) Market Drivers in Global Market

Table 3. Healthcare Nanotechnology (Nanomedicine) Market Restraints in Global Market

Table 4. Key Players of Healthcare Nanotechnology (Nanomedicine) in Global Market

Table 5. Top Healthcare Nanotechnology (Nanomedicine) Players in Global Market, Ranking by Revenue (2019)

Table 6. Global Healthcare Nanotechnology (Nanomedicine) Revenue by Companies, (US$, Mn), 2016-2021

Table 7. Global Healthcare Nanotechnology (Nanomedicine) Revenue Share by Companies, 2016-2021

Table 8. Global Companies Healthcare Nanotechnology (Nanomedicine) Product Type

Table 9. List of Global Tier 1 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Healthcare Nanotechnology (Nanomedicine) Companies, Revenue (US$, Mn) in 2020 and Market Share

Table 11. By Type Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 12. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 13. By Type Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 14. By Application Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 15. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2016-2021

Table 16. By Application Healthcare Nanotechnology (Nanomedicine) Revenue in Global (US$, Mn), 2022-2027

Table 17. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2021 VS 2027

Table 18. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2016-2021

Table 19. By Region Global Healthcare Nanotechnology (Nanomedicine) Revenue (US$, Mn), 2022-2027

Table 20. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 21. By Country North America Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 22. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021

Table 23. By Country Europe Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2022-2027

Table 24. By Region Asia Healthcare Nanotechnology (Nanomedicine) Revenue, (US$, Mn), 2016-2021 continued

About us.The Market Insights is a sister company to SI Market research and The Market Insights is into reselling. The Market Insights is a company that is creating cutting edge, futuristic and informative reports in many different areas. Some of the most common areas where we generate reports are industry reports, country reports, company reports and everything in between. At The Market Insights, we give our clients the best reports that can be made in the market. Our reports are not only about market statistics, but they also contain a lot of information about new and niche company profiles. The companies that feature in our reports are pre-eminent. The database of the reports on market research is constantly updated by us. This database contains a broad variety of reports from the cardinal industries. Our clients have direct access online to our databases. This is done to ensure that the client is always provided with what they need. Based on these needs, we at The Market Insights also include insights from experts about the global industries, market trends as well as the products in the market. These resources that we prepare are also available on our database for our esteemed clients to use. It is our duty at The Market Insights to ensure that our clients find success in their endeavors and we do everything that we can to help make that possible.

Direct ContactJessica Joyal+91-9284395731 | +91 9175986728sales@themarketinsights.com

See the rest here:
Healthcare Nanotechnology (Nanomedicine) Market Trend, Technology Innovations and Growth Prediction 2021-2027 The Manomet Current - The Manomet...

Read More...

Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – PRNewswire

Tuesday, August 17th, 2021

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ --The global regenerative medicine marketsize is expectedto reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Key Insights & Findings:

Read 273 page research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027", by Grand View Research

Furthermore,advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Grand View Research has segmented the global regenerative medicine market on the basis of product, therapeutic category, and region:

List of Key Players of Regenerative Medicine Market

Check out more studies related to Global Biotechnology Industry, conducted by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Go here to see the original:
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. - PRNewswire

Read More...

Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 – The Market Writeuo – The…

Tuesday, August 17th, 2021

The Latest research study released by DBMR Global Nanotechnology Market with 350+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that aid the market growth. The report shows market share, size, trends, growth, trends, applications, competition analysis, development patterns, and the correlations between the market dynamics and forecasts for 2020 to 2027 time-frames. The report aims to provide an overview of global Nanotechnology Market with detailed market segmentation by product/application and geography. The report provides key statistics on the Market status of the players and offers key trends and opportunities in the market. Research report has been compiled by studying the market in-depth along with drivers, opportunities, restraints & other strategies as well as new-developments that can help a reader to understand the exact situation of the market along with the factors that can limit or hamper the market growth and the report also has been updated with Impacts & effects of Coronavirus pandemic and how it has influenced consumer behavior& the growth of the market as well as industries.

The Global Nanotechnology Market is expected to reach USD 24.56 billion by 2025, from USD 7.24 billion in 2017 growing at a CAGR of 16.5% during the forecast period of 2020 to 2025

Download Free Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this [emailprotected]https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanotechnology-market&ab

Nanoscience is the study of extremely small things. The development of nanotechnology is being growing in many fields, as it has various applications, such as in chemistry, biology, physics, materials science and engineering. Nanotechnology deals with the use of nanoparticle of size of 1 to 100 nm to be used in all major field of medical. Materials designed from nanotechnology are lighter, stronger and more durable. In oncology research, nanotechnology assists in cancer eradication. Nanotechnology based device are also used in fitness monitoring. Smartphone apps and bracelets are developed based on nanotechnology concept. A nano based device is used to sense the body temperature, heartbeat and others which are sent back to the reader. After analysing the temperature and heartbeat, medical staff monitors the condition. All these nano based devices helps to drive the market. For elder people, battery-free printed graphene sensors are also developed which helps in gathering the health condition of the elder population, enables remote healthcare and improves the quality of life. In diagnostic and prevention, nanotechnology plays a vital role in cancer diagnostics. Nanotechnology based devices can detects the biomarker produced by the circulating tumor cells (CTCs) on the onset of cancer. Based on nanotechnology, two main methods of circulating tumor cells (CTC) isolations are magnetic and microfluidic methods. In clinical development fluorescent nano sensors are used for in-vivo monitoring of biomarkers. Another application of nanotechnology is nanomedicine which has potential application in diagnosis and therapy medicine for regeneration of tissues and organs.

This Nanotechnology Market 2020 Reportencompasses an infinite knowledge and information on what the markets definition, classifications, applications, and engagements are and also explains the drivers and restraints of the market which is obtained from SWOT analysis. By applying market intelligence for this Nanotechnology Market report, industry expert measure strategic options, summarize successful action plans and support companies with critical bottom-line decisions. Additionally, the data, facts and figures collected to generate this market report are obtained forms the trustworthy sources such as websites, journals, mergers, newspapers and other authentic sources. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

According to this reportGlobal Nanotechnology Marketwill rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Nanotechnology Market includes comprehensive information derived from depth study on Nanotechnology Industry historical and forecast market data. Global Nanotechnology Market Size To Expand moderately as the new developments in Nanotechnology and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @https://www.databridgemarketresearch.com/covid-19-impact/global-nanotechnology-market?ab

Nanotechnology Market report provides depth analysis of the market impact and new opportunities created by theCOVID19/CORONAVirus pandemic. Report covers Nanotechnology Market report is helpful for strategists, marketers and senior management, And Key Players in Nanotechnology Industry.

List of Companies Profiled in the Nanotechnology Market Report are:

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanotechnology-market&Ab

Nanotechnology Reportdisplays data on key players, majorcollaborations, merger & acquisitions along with trending innovation and business policies. The report highlights current and future market trends and carries out analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Nanotechnology market report include market definition, market segmentation, key developments, competitive analysis and research methodology. To accomplish maximum return on investment (ROI), its very essential to be acquainted with market parameters such as brand awareness, market landscape, possible future issues, industry trends and customer behavior where this Nanotechnology report comes into play.

The Segments and Sub-Section of Nanotechnology Market are shown below:

By Type (Nano composites, Nano materials, Nano tools, Nano devices, Others)

By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others)

By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others

Market Size Segmentation by Region & Countries (Customizable):

Key questions answered

What impact does COVID-19 have made on Global Nanotechnology Market Growth & Sizing?

Who are the Leading key players and what are their Key Business plans in the Global Nanotechnology market?

What are the key concerns of the five forces analysis of the Global Nanotechnology market?

What are different prospects and threats faced by the dealers in the Global Nanotechnology market?

What are the strengths and weaknesses of the key vendors?

Market Segmentation: Global Nanotechnology Market

The global nanotechnology market is segmented based on product type, application, industry and geographical segments.

By Product Type (Nano Composites, Nano Materials, Nano Tools, Nano Devices, Others), By Applications (Healthcare, Environment, Energy, Food & Agriculture, Information & Technology, Others), By Industry (Electronics, Cosmetics, Pharmaceutical, Biotechnology, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Based on product type , the market is segmented into nano-composites and nano materials, nano tools, nano devices, and others. Nano-composites are further sub segmented into nanoparticles, nanotubes and nano clays. Nano materials are further sub-segmented into nano fibers, nano ceramic products and nano magnetics. Nano tools are further sub-segmented into nanolithography tools and scanning probe microscopes. Nanodevices are further sub-segmented into nanosensors and nanoelectronics.

On the basis of application, the market is further segmented into healthcare, environment, energy, food & agriculture, information & technology and others.

Based on industries, the market is segmented into electronics, cosmetics, pharmaceutical, biotechnology and others.

Based on geography, the market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Strategic Points Covered in Table of Content of Global Nanotechnology Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Nanotechnology market

Chapter 2: Exclusive Summary the basic information of the Nanotechnology Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Nanotechnology

Chapter 4: Presenting the Nanotechnology Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Nanotechnology market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2020-2027).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Nanotechnology Market is a valuable source of guidance for individuals and companies in decision framework.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read more:
Nanotechnology Market Share, Industry Size, Leading Companies Outlook, Upcoming Challenges and Opportunities till 2028 - The Market Writeuo - The...

Read More...

Global Nanomedicine Market is Expected to Grow at an Impressive CAGR by 2028 The Manomet Current – The Manomet Current

Tuesday, August 17th, 2021

DBMR has added a new report titled Global Nanomedicine Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. This Report performs the methodical and comprehensive market research study that puts forth the facts and figures linked with any subject about industry. It all-inclusively estimates general market conditions, the growth prospects in the market, possible restrictions, significant industry trends, market size, market share, sales volume and future trends. A team of skilled analysts, statisticians, research experts, enthusiastic forecasters, and economists work painstakingly to structure such a great market report for the businesses seeking a potential growth. A Global Nanomedicine Market analysis report is generated with the best and advanced tools of collecting, recording, estimating, and analyzing market data.

Major insights of the realistic Global Nanomedicine Market report are complete and distinct analysis of the market drivers and restraints, major market players involved like industry, detailed analysis of the market segmentation and competitive analysis of the key players involved. Market segmentation categorizes the market depending upon application, vertical, deployment model, end-user, and geography etc. This global market document also presents an idea about consumers demands, preferences, and their altering likings about particular product. Furthermore, big sample sizes have been utilized for the data collection in the winning Global Nanomedicine Market report which suits the necessities of small, medium, as well as large size of businesses.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global Nanomedicine Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

Here is the original post:
Global Nanomedicine Market is Expected to Grow at an Impressive CAGR by 2028 The Manomet Current - The Manomet Current

Read More...

Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray – Newsweek

Tuesday, August 17th, 2021

Vaccinated citizens can still transmit the COVID-19 virus and its variants to other people. Salvacion USA Inc. is therefore excited to introduce the development of a complementary product, designed for adults 18 and older, it hopes could accompany COVID-19 vaccines to offer additional protection: a nasal spray to shield the nasal passages and prevent further viral transmission. (However, CDC guidelines should still be followed, and those who are eligible should receive the COVID-19 vaccination.)

COVID-19 vaccination numbers in the U.S. have now reached nearly 50 percent, and Americans are eager to resume life post-pandemic. However, as flu season approaches and the COVID-19 vaccines' efficacy and longevity have come under question, communities are increasingly concerned about the virus and its Delta and unknown variantsespecially as children return to school this fall. Experts have also speculated this pandemic could become endemic, cycling from season to season. For these reasons, we must continue to stay ahead of the rapidly updating situation and arrive at innovative strategies.

Salvacion's new technology is gaining momentum among the scientific community. The National Cancer Instituteestablished Nanotechnology Characterization Laboratory (NCL) recently selected Salvacion USA Inc. as one of its Assay Cascade awardees for Salvacion's nasal spray, trade name: COVIXYL-V. The announcement appeared in NCL's June 2021 quarterly newsletter, in which Salvacion noted, "COVIXYL-V is intended to reduce SARS-CoV-2 in nasal passages, a main point of entry for the virus in humans. Our unique virus-blocking product, optimized in collaboration with NCL, contains agents which block the virus from attaching to tissue and reducing the viral load in the tissue milieu."

According to NCL's announcement, "Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies."

Among Nanotechnology Characterization Laboratory's's five awardees, Salvacion is the only one working on a product intended to avert the spread of COVID-19. As an Assay Cascade awardee, NCL commits to funding Salvacion studies free of charge.

Ryan Hwang, a Salvacion spokesman, said, "Our product is preventative and protects nasal passages, halting transmission. Vaccines are developed to protect against COVID-19, but they are not designed to stop transmission. Our strategy is complementary to the effectiveness of vaccines by deterring COVID-19 infection by blocking the transmission."

Salvacion's clinical human trials are currently underway. In vitro and in vivo testing performed thus far suggested that the nasal spray inhibited 99.99 percent of COVID-19. This spray effectively blocked COVID-19 activity in the nasal passages of hamsters, the prime entry points for the virus. One study, performed by an independent BSL-3 laboratory (which, according to Public Health Emergency, is a lab "used to study infectious agents or toxins that may be transmitted through the air and cause potentially lethal infections"), showed that COVID-19 was 99.99 percent inactivated post-spray, with no clinical symptoms experienced by Syrian hamsters from the treatment. No adverse reactions were reported in the hamsters following administration. The data developed in this study showed that the nasal spray product was effective in neutralizing the virus within low concentrations. An additional barrier effect animal study undertaken at an independent laboratory also assessed the COVID-19 blocking effects of the nasal spray. It concluded that the spray created a physical barrier to block the viral particles from taking hold on the surface of the nasal passages. The testing was to prove the mechanism of the nasal spray is capable of blocking the transmission of COVID-19 by creating a physical barrier. The next step is the conducting of a human clinical trial, which is now underway. Salvacion is currently seeking an Emergency Use Authorization (EAU) for its COVIXYL-V nasal spray from the FDA.

This nasal spray is made of ingredients listed as GRAS, or "Generally Recognized As Safe," by the FDA. Unlike other products based on isopropyl alcohol currently being tested, it appears Salvacion's nasal spray could offer a unique blocking system with enhanced effectiveness at a very low concentration. A worldwide patent has been filed for this technology.

"Our nasal spray product may well be the key to moving back to a world that some have thought lost forever to the 'new normalcy,'" said Abdul Gaffar, a Salvacion chemist and recipient of the American Chemistry Society's Heroes of Chemistry Award, who invented this nasal spray.

The contents of this article are for informational purposes only and do not constitute medical advice. It's important to consult with your medical providers and the CDC before making any medical decisions or changes to your health plan, particularly with regard to COVID-19 and its variants.

Read this article:
Complementary Protection May Be at Hand With a COVID-19-Preventing Nasal Spray - Newsweek

Read More...

Nanorobotics Market By Player, Region, Type, Application And Sales Channel, Regions, Type and Application, Revenue Market Forecast to 2028 – Digital…

Tuesday, August 17th, 2021

Rising investment in urgent care and increasing global geriatric population are key factors driving revenue growth of the global nanorobotics market

The globalNanorobotics marketsize is expected to reach USD 14.03 Billion in 2028 and register a CAGR of 10.9% over the forecast period, according to the latest report by Emergen Research. Nanorobotics market revenue growth is driven by key factors such as rapid innovations in nanorobotics technology and increasing application of the technology in treatment of neurological cardiovascular, oncological, infectious, orthopedic diseases, and others.

Nanorobotics is the technology which creates robots or machines at a very small scale. The field of nanorobotics brings together various disciplines, including nanofabrication processes used for producing nanoactuators, nanomotors, and nanosensors, among others. Rising focus on regenerative medicine coupled with technological advancements is boosting market revenue growth. Furthermore, increasing adoption of medical equipment and more advanced technologies such as Machine Learning (ML) and Artificial Intelligence (AI) is driving growth of the global nanorobotics market, and the trend is expected to continue going ahead.

Access full Report Description, TOC, Table of Figure, [emailprotected] https://www.emergenresearch.com/request-sample/744

Some Key Highlights From the Report

Key Growth Prospects:The report specializes in examining the major growth prospects of the global Nanorobotics market, such as new product launches, collaborations, joint ventures, mergers & acquisitions, agreements, partnerships, and the progress of the key market players functioning in the market, on regional and global levels.

The market intelligence report exhaustively examines the market value, share, demand, growth prospects, latest and historical trends, manufacturers, gross revenue collection, competitive terrain, market growth forecast, available products, and end-use applications.

Geographical Terrain of the Global Nanorobotics Market:

Please connect with our representative to get a Inquiry Of the Nanorobotics [emailprotected] https://www.emergenresearch.com/request-sample/744

For the purpose of this report, Emergen Research has segmented the global nanorobotics market based on type, application, and region:

To Get This Report At A Profitable [emailprotected] https://www.emergenresearch.com/request-discount/744

Table Of content

Chapter 1. Market Synopsis 1.1. Market Definition 1.2. Research Scope & Premise 1.3. Methodology 1.4. Market Estimation TechniqueChapter 2. Executive Summary 2.1. Summary Snapshot, 2020-2028Chapter 3. Indicative MetricsChapter 4. Nanorobotics Market Segmentation & Impact Analysis 4.1. Nanorobotics Market Material Segmentation Analysis 4.2. Industrial Outlook 4.2.1. Market indicators analysis 4.2.2. Market drivers analysis 4.2.2.1. Rising Focus on Nanotechnology and Regenerative Medicine 4.2.2.2. Increasing Government Support and Level of Investment in Nanorobotics 4.2.3. Market restraints analysis 4.2.3.1. Implementation of Excise Tax and Heavy Custom Duty on 4.3. Technological Insights 4.4. Regulatory Framework 4.5. ETOP Analysis 4.6. Porters Five Forces Analysis 4.7. Competitive Metric Space Analysis 4.8. Price trend Analysis 4.9. Customer Mapping 4.10. Covid-19 Impact Analysis 4.11. Global Recession Influence

Chapter 5. Nanorobotics Market By Type Insights & Trends 5.1. Type Dynamics & Market Share, 2021 & 2028 5.2. Nanomanipulator 5.2.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3. Electron Microscope (EM) 5.2.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.3. Scanning Electron Microscope (SEM) 5.2.3.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.3.4. Transmission Electron Microscope (TEM) 5.2.3.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.3.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4. Scanning Probe Microscope (SPM) 5.2.4.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.3. Atomic Force Microscopes (AFM) 5.2.4.3.1. Market estimates and forecast, 2018 2028 (USD Million) 5.2.4.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.2.4.4. Scanning Tunneling Microscope (STM) 5.2.4.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.2.4.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.3. Bio-Nanorobotics 5.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.4. Magnetically Guided 5.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 5.5. Bacteria-Based 5.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 5.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Chapter 6. Nanorobotics Market By Application Insights & Trends 6.1. Application Dynamics & Market Share, 2021 & 2028 6.2. Nanomedicine 6.2.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.2.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.3. Biomedical 6.3.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.3.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.4. Mechanical 6.4.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.4.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion) 6.5. Others (Space and Oil & Gas) 6.5.1. Market estimates and forecast, 2018 2028 (USD Billion) 6.5.2. Market estimates and forecast, By Region, 2018 2028 (USD Billion)

Continue..!

Request customization of the report: https://www.emergenresearch.com/request-for-customization/744

Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you a report well-suited to your requirements.

Media ContactCompany Name: Emergen ResearchContact Person: Eric LeeEmail: Send EmailPhone: +1 (604) 757-9756Address:14671 110 Avenue Surrey, British Columbia, V3R2A9City: SurreyState: British ColumbiaCountry: CanadaWebsite: http://www.emergenresearch.com/industry-report/nanorobotics-market

Read the original post:
Nanorobotics Market By Player, Region, Type, Application And Sales Channel, Regions, Type and Application, Revenue Market Forecast to 2028 - Digital...

Read More...

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board – Yahoo Eurosport UK

Tuesday, August 17th, 2021

DGAP-News: MagForce AG / Key word(s): AGM/EGM12.08.2021 / 17:15 The issuer is solely responsible for the content of this announcement.

MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board

Berlin, Germany, and Nevada, USA, August 12, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the results of the 2021 Annual General Meeting (AGM). Due to the COVID-19 pandemic, the meeting was held virtually, as in the previous year. In total, 44.5 percent of the share capital with voting rights was represented.

The Annual General Meeting approved resolution items 2 to 5 as well as 7, 8 and 10 - most of them with a significant majority. Resolution item 6 (Authorized Capital 2021) did not receive the required qualified majority. Norbert Neef, Chairman of the Supervisory Board, informed the Annual General Meeting that he resigns from office effective as of the end of the AGM. Thus, the vote on agenda item 9 was not applicable. Following the suggestion of the supplementary motion of shareholder Avalon Capital One GmbH dated July 29, 2021, Stefan Schtze, attorney and Managing Director of C3 Management GmbH, was elected to the Supervisory Board from the end of this AGM until the end of the AGM that resolves on the ratification of the actions of the members of the Supervisory Board for fiscal year 2021. The Supervisory Board of MagForce AG, which also includes Klemens Hallmann and Aaron Weaver, will hold a constituent meeting shortly to vote on the new chair.

Ben Lipps, CEO of MagForce AG and MagForce USA, Inc.: "From the Management as well as the employees of MagForce, I would like to express my sincere gratitude. Norbert has overseen the Company through its formative years and contributed significantly to the constructive cooperation between the Supervisory Board and the Executive Board that has supported the important decisions in corporate strategy and direction. As a result we have two unique and effective treatment options for glioblastoma and focal intermediate risk prostate cancer. The Management Board wishes Norbert every success in his professional as well as private future. At the same time, we welcome Mr Schtze as new member of the Supervisory Board and look forward to working together to achieve further important milestones for MagForce."

Additional information on the 2021 Annual General Meeting 2021, including detailed voting results, the video address by CEO Ben J. Lipps, as well as the Management presentation on current operational developments, the overview of fiscal year 2020 and outlook for the current year, are available on the Company's website at https://www.magforce.com/en/home/for-press-investors/#general_meetings.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc., is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(R) therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.

NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

For more information, please visit: http://www.magforce.comGet to know our Technology: video (You Tube)Stay informed and subscribe to our mailing list

Contact:MagForce AGBarbara von FrankenbergVice President Communications & Investor RelationsT +49-30-308380-77E-Mail: bfrankenberg@magforce.com

Disclaimer

This release may contain forward-looking statements and information which may be identified by terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

12.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Original post:
MagForce AG announces results of 2021 Annual General Meeting and changes to the Supervisory Board - Yahoo Eurosport UK

Read More...

McMaster University researchers awarded more than $3M in Federal funds for projects – insauga.com

Tuesday, August 17th, 2021

Eleven researchers working out of Hamilton's McMaster University have been awarded almost $3.3 million from the Federal Government for projects deemed to be "on the cutting edge of science andinnovation."

On Wednesday (Aug. 11), Francois-Philippe Champagne, Minister of Innovation, Science and Industry, announced that more than $77 million had been earmarked to support 332 research infrastructure projects at 50 universities acrossCanada.

The funding, made possible through the Canada Foundation for Innovation's (CFI) John R. Evans Leaders Fund (JELF), is expected to help universities attract and retain topresearchers.

"From developing sustainable building materials to creating new laboratories based on Indigenous principles and community engagement, these awards support essential and urgent research," said CFI president and CEO Roseann O'Reilly Runte, in a pressrelease.

"With the necessary spaces and tools, Canada's researchers will play a meaningful role on the global stage and contribute significantly to the quality of life today and for generations tocome."

The more than $3 million going to Mac researchers will help advance their work in health, materials and electrificationresearch.

Projects at Mac that will benefit from the fundinginclude:

Faculty ofEngineering

Bilgen Berker, Electrical and Computer Engineering Project: An Acoustic Noise and Vibration Measurement Facility for Low-noise and High-efficiency Electric Motor DrivesAward:$200,000

Ryan Lewis, Engineering Physics Project: Advanced Epitaxial Nanostructures and Materials LaboratoryAward:$190,584

Zahra Keshavarz-Motamed, Mechanical Engineering Project: Developments of Diagnostic and Predictive Tools and Regulatory Device Testing Machines for Cardiovascular DiseasesAward:$185,000

Maureen Lagos Paredes, Materials Science & Engineering Project: Momentum-resolved EELS Spectroscopy of Beam-sensitive Nanoscale MaterialsAward:$387,788

Faculty of HealthSciences

Lisa Carlesso, Rehabilitation Science Project: Understanding Pain Mechanisms and Management in Neuromusculoskeletal RehabilitationAward:$129,000

Michael McGillion, Nursing Project: Improving Perioperative and canceR Outcomes Through Excellence and appliCation of Virtual Technologies (PROTECT) LabAward:$800,000

Ishac Nazy, Medicine Project: Investigating Novel Mechanisms in Immune-mediated Platelet DisordersAward:$160,000

Michael Surette, Medicine Project: Metagemomics and Genomics of the Microbiome, Infectious Disease and Host ResponseAward:$650,000

Faculty ofScience

Katherine Bujold, Chemistry & Chemical Biology Project: Establishment of Nucleic Acid Nanomedicine Laboratory at McMaster UniversityAward:$75,005

Katrina Choe, Psychology, Neuroscience & Behaviour Project: Neural Mechanisms Linking Autism-risk Genes with Impaired Social BehaviorAward:$400,000

Jeremy Walsh, Kinesiology Project: Integrative Psychophysiology Research LabAward:$100,000

A full list of research projects and funding recipients benefitting from this investment can be found on the CFI website.

Read more:
McMaster University researchers awarded more than $3M in Federal funds for projects - insauga.com

Read More...

Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network – The Bisouv Network

Sunday, February 14th, 2021

Nanotechnology in Medical Applications: The Global Market

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

Also Read:https://telegra.ph/Global-Dancewear-Market-Statistics-Development-and-Growth-2025-02-02

Report Includes:

Also Read: http://wiseguyes8.total-blog.com/global-china-digital-audio-broadcasting-dab-market-outlook-industry-analysis-and-prospect-2020-2026-22894697

An overview of the global markets for nanotechnology used in medical applications

Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022

A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications

Also Read: https://techsite.io/p/1944999

Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness

A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine

Analysis of the markets dynamics, specifically growth drivers, inhibitors, and opportunities

Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive marketSummary

Also Read:https://wiseguyreports12.blogspot.com/2021/02/global-china-digital-audio-broadcasting.html

Nano-enabled medical products began appearing on the market over a decade ago, and some have become best-sellers in their therapeutic categories. The principal areas in which nanomedical products have made an impact are cancer, CNS diseases, cardiovascular disease and infection control. The Summary Table gives estimates of the historical and current markets for these nanomedicine areas with a forecast through 2022.

The U.S. market is by far the largest in the global nanomedicine market and is set to continue to dominate the world marketplace; however, other national markets are expected to increase their shares over the next five years.

Reasons for Doing the Study

Also Read:https://penzu.com/p/240d32a5

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced some significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.ABLYNX NV

ABRAXIS BIOSCIENCE (CELGENE)

APHIOS CORP.

BIOFORCE NANOSCIENCES HOLDINGS INC.

BIO-GATEAG

CALANDO PHARMACEUTICALS INC.

C SIXTY INC. (ARROWHEAD PHARMACEUTICALS)

ELAN (ALKERMES CORP.)

FARFIELD SCIENTIFIC (BIOLIN SCIENTIFIC AB)

IGI LABORATORIES (TELIGENT INC.)

KEREOS INC.

KEYSTONE NANO INC.

KLEINDIEK NANOTECHNIKGMBH

LABOPHARM (PALADIN LABS)

LIPLASOME PHARMA APS

MAGFORCE NANOTECHNOLOGIES

MAGNAMEDICS GMBH

MICROFLUIDICS CORP.

MOLECULAR PROFILES (JUNIPER PHARMA SERVICES)

NANOBIO CORP.

NANOBIOTIX

NANOCARRIER CO. LTD

NANOCOPOEIA, INC.

NANOCYTE INC.

NANOLOGIX INC.

NANOMED PHARMACEUTICALSINC.

NANOMIX INC.

NANOPHARM AG

NANOSPECTRA BIOSCIENCESINC.

NANOSPHERE INC. (LUMINEX CORP.)

NANOSTRUCTURES INC.

NANOSYN INC.

NANOTHERAPEUTICS INC.

NANOTROPE INC.

NANOVIRICIDES INC

NUCRYST PHARMACEUTICALS

NUTRALEASE

ORTHOVITA INC. (STRYKER CORP.)

PIONEER SURGICAL TECHNOLOGY (RTI SURGICAL)

PSIVIDA LTD.

SOLUBEST LTD

STARPHARMA

TECANGROUP LTD.

TRANSGENEX NANOBIOTECH INC.

FOR MORE DETAILS :https://www.wiseguyreports.com/reports/5545026-global-plastic-and-competitive-pipe-market-insights-and-forecast-to-2016

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Us:

NORAH TRENT

[emailprotected]

Ph: +162-825-80070 (US)

Ph: +44 2035002763 (UK)

Here is the original post:
Global NANOTECHNOLOGY IN MEDICAL APPLICATIONS Statistics, CAGR, Outlook, and Covid-19 Impact 2016 The Bisouv Network - The Bisouv Network

Read More...

Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The…

Sunday, February 14th, 2021

TheNanotechnology in Medical market outlooklooks extremely promising is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope and application of this report.

The report presents the market competitive landscape and a corresponding detailed analysis of the majorvendor/key playersin the market.Top Companiesin the Global Nanotechnology in Medical Market:Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune, Access, Camurus, Roche, Dentsply International, 3M, Celgene, Pfizer.

SPECIAL OFFER (Avail an Up-to 25% discount on this report, please fill the form and mention the code: MIR25 in the comments section)

Click the link to get a free Sample Copy of the Report@:

https://www.marketinsightsreports.com/reports/01122532008/global-nanotechnology-in-medical-market-research-report-with-opportunities-and-strategies-to-boost-growth-covid-19-impact-and-recovery/inquiry?source=Now&Mode=24

This report segments the global Nanotechnology in Medical market on the basis ofTypesare:

Nano Medicine

Nano Diagnosis

Other

On the basis ofApplication, the Global Nanotechnology in Medical market is segmented into:

Hospitals

Clinics

Others

Investigator Observers Strong Growth in Specific Regions:

EuropeMarket (Germany, UK, France, Russia, Italy)

Center East and AfricaMarket (Saudi Arabia, UAE, Egypt, Nigeria, South Africa)

South AmericaMarket (Brazil, Argentina, Colombia)

North AmericaMarket (United States, Canada, Mexico)

Asia PacificMarket (China, Japan, Korea, India, Southeast Asia).

Inquire For Discount at:

https://www.marketinsightsreports.com/reports/01122532008/global-nanotechnology-in-medical-market-research-report-with-opportunities-and-strategies-to-boost-growth-covid-19-impact-and-recovery/discount?source=Now&Mode=24

Influence of the Nanotechnology in Medical market report:

-Comprehensive assessment of all opportunities and risk in the Nanotechnology in Medical market.

-Nanotechnology in Medical market recent innovations and major events

-Detailed study of business strategies for growth of the Nanotechnology in Medical market-leading players.

-Conclusive study about the growth plot of Nanotechnology in Medical market for forthcoming years.

-In-depth understanding of Nanotechnology in Medical market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the Nanotechnology in Medical market.

Important Features that are under Offering and Key Highlights of the Reports:

Detailed overview of Market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth.

Finally, the Nanotechnology in Medical Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. Nanotechnology in Medical Industry report additionally Presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

MediaContact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

See the article here:
Nanotechnology in Medical Market Demand Analysis To 2026 Lead By-Smith and Nephew, Novartis, Merck, Mitsui Chemicals, Amgen, Cytimmune KSU | The...

Read More...

NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety…

Tuesday, February 9th, 2021

SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc.. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based on a novel nanomedicines platform has announced today that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections was well tolerated in safety pharmacology studies required for progressing to human clinical trials.

The Company reports that its drug candidate NV-CoV-2 was found to be safe in the GLP safety pharmacology studies performed by an external contract research organization (CRO) in both rat and non-human primate (NHP) models. Additionally, multiple injections of NV-CoV-2 were also well tolerated in an extensive non-GLP study in rats that was performed by AR Biosystems, Inc., FL.

Based on the safety of NV-CoV-2 in these studies, the Company believes that projected dosages would be safe in human clinical trials. With these findings, the Company believes that it will be possible to administer repeated dosages of NV-CoV-2 in a human clinical trial, if needed, to achieve control over the coronavirus infection from SARS-CoV-2 or its variants.

In a GLP neuro-pulmonary safety pharmacology study in rats, the following conclusion was drawn: The intravenous administration of NV-CoV-2 at doses of 25, 50 and 100 mg/kg did not affect respiratory function in rats.

In a GLP cardiovascular function study in the NHP cynomolgus monkeys, the following conclusion was drawn: Intravenous infusion of NV-CoV-2 at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology in cynomolgus monkeys in this study. No significant effects on blood pressure and heart rate were observed after the intravenous infusion of NV-CoV-2.

These results were consistent with a more extensive, multiple injection non-GLP safety and tolerability study in Sprague-Dawley male and female rats. In this non-GLP study, NV-CoV-2 was injected intravenously (via tail vein) on each of days 0, 1, 2, 3, 4, and 5. Two different doses were used: 320mg/kg BW per injection, and 160 mg/kg BW per injection. Clinical observations, body weight, urine, blood chemistry, post-mortem findings, and organ histology were studied. In all parameters, NV-CoV-2 was well tolerated at both dosages throughout the study.

The Company has received draft reports from all of these studies. We anticipate receiving final audited reports on the GLP studies shortly.

The Company is preparing to submit a pre-IND application to the US FDA with safety tolerability and effectiveness data to obtain guidance regarding human clinical trials. Additionally, we are actively seeking opportunities to engage appropriate sites for human clinical trials. Further, we are engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA.

The need for the broad-spectrum, pan-coronavirus nanoviricide drug treatment cannot be overstated for combating the COVID-19 pandemic given the current circumstances and the present status of the pandemic. New virus variants continue to develop in the field. The variants that have advantages in terms of transmissibility, infectivity, and escape from drugs and vaccines will continue to evolve and spread, replacing prior variants. This is already well documented.

Several vaccines have been found to be substantially less effective in protecting against infection by the South African variant, N501Y-V.2 (also called lineage B.1.351) than the earlier variants. A mutation present in B.1.351 as well as Brazilian variant P.1 that is thought to be possibly linked to evasion from antibody drugs and vaccines, E484K, has also been reported in UK in a further differentiated mutant of the variant of concern lineage B.1.1.7. The available monoclonal antibody drugs and convalescent plasma antibodies have been reported to be less effective against several variants.

By the very nature of how they work, vaccines and antibodies tend to be highly specific to the target virus variant, and do not afford strong protection against differentiated variants that are evolutionary distant from the target variant. This scientific fact is now well demonstrated for the COVID-19 pandemic.

It is therefore clear that an effective broad-spectrum anti-coronavirus drug will be needed before the world can return to normal activity.

The Company previously had advanced NV-CoV-1 and had continued to work further with additional drug candidates. One of these drug candidates, namely, NV-CoV-2 was found to have several advantages over NV-CoV-1 in terms of manufacturability and dose formulation. Therefore the Company has advanced NV-CoV-2 into GLP safety/pharmacology studies.

NanoViricides is developing a broad-spectrum antiviral drug where the potential for escape of virus variants is minimized by the very design of the drug for the treatment of COVID-19 infected sick persons. In contrast, vaccines are not treatments for sick persons, and must be administered to healthy individuals, and further require several weeks for the recipient's immune system to become capable of protecting against the target virus strain which still may not protect against new virus variants circulating by that time.

NanoViricides has a strong advantage in that the Company has its own cGMP-capable manufacturing facility in Shelton, CT. This facility is capable of producing approximately 4kg of the COVID-19 drug per batch. We anticipate that this would be sufficient for human clinical trials, and possibly for initial introduction under Compassionate Use, Emergency Use Authorization or similar regulatory approval.

"We are pleased with the results of the safety pharmacology studies, and now we are confident that our COVID-19 drug candidate can advance into human clinical trials," said Anil R. Diwan, PhD, President and co-Founder of NanoViricides, Inc., and co-Inventor of its platform technologies and drug candidates.

About NanoViricides

NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.

The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with remdesivir encapsulated in it. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines.

Contact:NanoViricides, Inc.info@nanoviricides.com

Public Relations Contact:MJ ClyburnTraDigital IRclyburn@tradigitalir.com

SOURCE: NanoViricides, Inc.

View source version on accesswire.com:https://www.accesswire.com/628273/NanoViricidess-Broad-Spectrum-Antiviral-Drug-Candidate-for-the-Treatment-of-COVID-19-Infections-was-Well-Tolerated-in-GLP-and-non-GLP-Animal-Safety-Studies

View post:
NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety...

Read More...

Nanorobots In Blood Market Top-Vendor And Industry Analysis By End-User Segments Till 2028 | Aries Chemical, GE Water & Process Technologies KSU…

Tuesday, February 9th, 2021

The Global Nanorobots In Blood Market Research Report Forecast 2021-2028 is a valuable source of insightful data for business strategists. It provides the Nanorobots In Blood industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Nanorobots In Blood market study provides comprehensive data which enhances the understanding, scope and application of this report.

Request a Free sample Copy of this premium https://www.qyreports.com/request-sample/?report-id=193594

Key Players:

Nanorobots In Blood Market Segment by Solution Type, covers:

Nanorobots In Blood Market Segment by Application, covers:

Key Benefits

The report provides a qualitative and quantitative analysis of the current Nanorobots In Blood Market trends, forecasts, and market size from 2021 to 2028 to determine the prevailing opportunities. Porters Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry. Top impacting factors & major investment pockets are highlighted in the research. The major countries in each region are analysed and their revenue contribution is mentioned. The Nanorobots In Blood Market report also provides an understanding of the current position of the market players active in the small satellite industry.

The report begins with a brief introduction and Nanorobots In Blood market overview of the Nanorobots In Blood industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed, along with current trends and policies in the industry.

Request a discount on standard prices of this premium research https://www.qyreports.com/ask-for-discount/?report-id=193594

The report provides a detailed study of the growth rate of every segment with the help of charts and tables. Furthermore, various regions related to the growth of the market are analysed in the report.

Global Nanorobots In Blood Market: Regional Segment Analysis

Besides this, the research demonstrates the growth trends and upcoming opportunities in every region.

Analysts have revealed that the Nanorobots In Blood Market has shown several significant developments over the past few years. The report offers sound predictions on market value and volume that can be beneficial for the market players, investors, stakeholders, and new entrants to gain detailed insights and obtain a leading position in the market.

Additionally, the report offers an in-depth analysis of key market players functioning in the global Nanorobots In Blood industry.

Furthermore, it throws light on key business priorities in order to assist the companies. The global Nanorobots In Blood Market report summarized with different case studies from leading industries, policymakers, business owners, and industry experts. The growth predictions for numerous segments have been included in the report.

Reasons for Buying this Report:

Enquiry Before Buying https://www.qyreports.com/enquiry-before-buying/?report-id=193594

About QYReports:

We at QYReports, a leading market research report publisher cater to more than 4,000 prestigious clients worldwide meeting their customized research requirements in terms of market data size and its application. Our list of customers include renowned Chinese companys multinational companies, SMEs and private equity firms. Our business study covers a market size of over 30 industries offering you accurate, in depth and reliable market insight, industry analysis and structure. QYReports specialize in forecasts needed for investing in and execution of a new project globally and in Chinese markets.

Contact Us:

Name: Jones John

Contact number: +1-510-560-6005

204, Professional Center,

7950 NW 53rd Street, Miami, Florida 33166

sales@qyreports.com

http://www.qyreports.com

Read this article:
Nanorobots In Blood Market Top-Vendor And Industry Analysis By End-User Segments Till 2028 | Aries Chemical, GE Water & Process Technologies KSU...

Read More...

Precision NanoSystems Receives Contribution from the Government of Canada to Build RNA Medicine Biomanufacturing Centre – PRNewswire

Wednesday, February 3rd, 2021

"Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure that Canada has modern, flexible vaccine manufacturing capabilities now and in the future. With the investments announced today, our government is helping Canadian companies advance made-in-Canada vaccines and therapies, while securing domestic manufacturing options for international vaccine candidates. This is all part of our government's commitment to protect the health and safety of all Canadians today, and in the future", said the Honourable Franois-Philippe Champagne, Minister of Innovation, Science and Industry.

PNI supports the development of genetic medicines by providing products and services to its clients worldwide who are creating new treatments for infectious diseases, rare diseases, cancer and other areas of unmet need. This project will help PNI establish a Biomanufacturing Centre that will expand Canada's epidemic and pandemic preparedness capacity and will enable PNI to expand its development and manufacturing services to support the clinical development and supply of new medicines.

"PNI's centre of manufacturing excellence of nanomedicine will be a state-of-the-art facility for the development and manufacture of genetic therapeutics and vaccines," James Taylor, CEO, Precision NanoSystems stated. "The centre will continue Canada's leadership in the creation of innovative solutions for the development and production of new medicines for the benefit of patients in Canada and beyond. This support from the Government of Canada helps PNI to further achieve our mission of accelerating the creation of transformative medicines that significantly impact human well-being."

About Precision NanoSystems Inc. (PNI)

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine.PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

SOURCE Precision Nanosystems

http://www.precisionnanosystems.com

View post:
Precision NanoSystems Receives Contribution from the Government of Canada to Build RNA Medicine Biomanufacturing Centre - PRNewswire

Read More...

Vaccine Production in BC’s Future – AM 1150 (iHeartRadio)

Wednesday, February 3rd, 2021

As part of the federal governmentsinvestment in domestic vaccine capability, a Vancouver company is taking their $25.1 million allotment to build a massive manufacturing facility in the Lower Mainland.

South Vancouver-basedPrecision Nanosystemsis building a $50.2 million biomanufacturing centre that could produce up to 240 million doses of vaccine every year in the 40,000 square foot facility. It's still assessing possible locations.

Its estimated completion date is March 2023, but the companys CEO says the investment is important on a number of levels.

"It's an investment in pandemic preparedness, an investment in the future, an investment in these critical technologies that are really the technologies of the future, said James Taylor in a Zoom interview. What were focussed on is the medium- to long-term pandemic responsiveness as well as developing capabilities and capacity around genetic medicine itself, so our facility will be able to utilize for programs that are involved in cancer, infectious diseases, rare diseases.

The same kind of messenger RNA technology that companies like Pfizer-BioNTech and Moderna have developed to quickly create and manufacture their successful COVID-19 vaccines is the same idea behind many local companies like Precision Nanosystems. Many members of the scientific community believe such genetic medicines that treat diseases at the molecular level are on the cusp of revolutionizing medicine.

"As long as you know how to create those instructions -- that genetic code you need to convince your body to create that target -- you can design an mRNA vaccine against any antigen," said Nicole Basta, an associate professor of epidemiology at McGill told the Canadian Press.

Vancouver-based Acuitas Therapeutics developed a lipid nanoparticle to protect the delicate messenger RNA strands that can be broken down by the body. https://www.ctvnews.ca/health/coronavirus/a-canadian-company-helped-make-one-of-the-most-promising-vaccine-candidates-1.5193860

Taylor described the Lower Mainland as a global hub in nano-medicines, pointing out the growing industry is deeply intertwined with researchers, scientists and experts working across borders on shared projects; Precision Nanosystems alone works with more than 160 other companies around the world.

This past a year has really shone a light on the importance of science and technology to solve deep problems globally, he said. It's important for us, as Canadians, to be strong participants in the development and innovation.

Read more from the original source:
Vaccine Production in BC's Future - AM 1150 (iHeartRadio)

Read More...

New facility to be built in Vancouver will produce 240 million vaccine doses annually | Urbanized – Daily Hive

Wednesday, February 3rd, 2021

As the battle against COVID-19 rages on, Canada is ramping up its vaccine producing capabilities at home in an effort to fill in the gaping hole in national security made evident by the pandemic.

Vancouvers Precision NanoSystems Inc. (PNI) announced this week it received $25.1 million from the federal governments Strategic Innovation Fund to create its domestic vaccine biomanufacturing capability.

The federal contribution covers half of the total $50.2 million cost of the new biomanufacturing centre that will be built in Vancouver, focusing on the production of ribonucleic acid (RNA) lipid nanoparticle vaccines and genetic medicines.

But the first vaccines made in this 40,000-sq-ft facility will not be ready for immediate pandemic needs; the project is not expected to reach completion until 2023, however, it will help secure the national supplies for critical medicines, future COVID-19 vaccine needs, and vaccines for future pandemics.

When operational, it will have a capacity to manufacture up to 240 million doses of vaccine each year. The RNA vaccine technology it will use is also currently being utilized by Pfizer-BioNTech and Moderna to rapidly develop and produce their COVID-19 vaccines.

PNIs centre of manufacturing excellence of nanomedicine will be a state-of-the-art facility for the development and manufacture of genetic therapeutics and vaccines, saidJames Taylor, the CEO of Precision NanoSystems, in a statement.

The centre will continueCanadasleadership in the creation of innovative solutions for the development and production of new medicines for the benefit of patients inCanadaand beyond.

Prior to COVID-19, PNI was already seeing quick growth in its business of developing genetic medicines by offering products and services to help create new treatments for infectious diseases, rare diseases, cancers, and other ailments.

PNI announced two separate COVID-19 vaccine development partnerships in May 2020, including a DNA vaccine with Edmonton-basedEntos Pharmaceuticals.

That same month, another partnership was entered with Chinese vaccine companyCanSino Biologics, with PNI responsible for the development of the mRNA vaccine and CanSino Biologics responsible for the pre-clinical testing, human clinical trials, regulatory approval, and commercialization. The Chinese company has the rights to commercialize the vaccine product in Asia, except in Japan, with PNI retaining the rights for the rest of the world.

A report in the Globe and Mail last summer indicated the federal governments National Research Council ended its partnership with CanSino, after the Chinese government refused to ship a vaccine to Canada for trials.

In October 2020, the federal government also provided $18.2 million in funding for PNI to advance a COVID-19 mRNA vaccine candidate to clinical trials.

Our government is bringing back the vaccine manufacturing capacity that Canadians expect and need. These investments will help to ensure thatCanadahas modern, flexible vaccine manufacturing capabilities now and in the future, saidFranois-Philippe Champagne, the federal Minister of Innovation, Science, and Industry, in a statement.

Our government is helping Canadian companies advance made-in-Canadavaccines and therapies, while securing domestic manufacturing options for international vaccine candidates.

The federal government is also funding new vaccine biomanufacturing facilities in Saskatchewan and Quebec.

Read the original:
New facility to be built in Vancouver will produce 240 million vaccine doses annually | Urbanized - Daily Hive

Read More...

Faster tracking of treatment responses – MIT News

Wednesday, February 3rd, 2021

In the fight against severe diseases like cancer, patients often endure a discomforting, weekslong gap between when treatment begins and when doctors can tell if its working. The problem often stems from an inability to track the diseases progression in anything close to real time.

Now Glympse Bio, a startup spun out of the lab of Sangeeta Bhatia, the John J. and Dorothy Wilson Professor of Electrical Engineering and Computer Science at MIT and director of the Marble Center for Cancer Nanomedicine, is working to shine a light on disease activity using tiny synthetic biosensors. After being injected into the body, the sensors travel to the disease site and measure protein changes associated with that disease. The sensors are then excreted in urine and analyzed using standard laboratory techniques.

The company believes its technology holds potential to transform disease detection, tracking, and by providing clinicians with data-driven insights treatment.

When a patient is put on a medicine, its really a waiting game, says Bhatia, Glympse Bio co-founder who is also a member of MITs Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science. Theres often nothing to do but wait to see if a disease is responding. We hope this technology can provide information to clinicians and patients earlier.

Glympse recently completed a Phase 1 trial of its sensors in patients with non-alcoholic steatohepatitis (NASH), a potentially deadly liver disease estimated to affect about 12 percent of adults in the U.S. Because the current process for diagnosing NASH involves sampling a piece of the liver through a biopsy, it often remains undetected until the disease is in its most advanced stages.

Glympse is also tuning its sensors to track the progression of certain cancers, infections, and inflammation. Success in those fields would give drug development companies, doctors, and patients a potent new tool in the fight against an array of life-threatening diseases.

With this platform you open up several different universes, Glympse CEO Caroline Loew says. For diseases that are harder to diagnose, you get to diagnose them faster, you get to be able to develop drugs for them more effectively, and you get to treat them faster.

Sensing an opportunity

Like many great scientific advances, the discovery that led to Glympse was serendipitous. Around 2008, Bhatias group was using tagged magnetic particles that travel to tumors in the body, where they could reveal their location through an MRI scan. In every cancer experiment, the researchers noticed the bladder lit up with the tag.

We realized we didnt need an imaging machine anymore, we could just give a shot and do a urine test, Bhatia says.

By 2012, Glympse co-founder Gabe Kwong, a postdoc in Bhatias lab between 2009 and 2014, had developed the tagging technology enough to map changes in protein activity to the progression of multiple diseases. Some of that early work was funded, in part, by the Koch Institute Frontier Research Program.

After some encouragement from her colleagues, Bhatia assembled a team of advisors including Institute Professor Robert Langer and secured a grant from MITs Deshpande Center to start the company. Bhatia eventually took a sabbatical from MIT to help the company identify its first target, NASH, raise venture capital, secure a partnership with the pharmaceutical company Gilead Sciences, and understand how the sensors would be regulated by the Food and Drug Administration.

The progress was enough to attract Loew, who had spent her career helping large pharmaceutical companies develop drugs. Loew says she was impressed by the breadth of insights Glympse could glean with its biosensor platform, which measures the activity of enzymes called proteases that are altered in a variety of serious diseases.

Loew led the company as its focus has broadened from diagnostics to precise disease tracking during treatment.

We began thinking about earlier cancer detection because you can save a lot of lives by finding cancer early, Bhatia says. Now were realizing that we can potentially understand whether new drugs are working and if the patients are on the right medicine.

The company believes it can understand not just if a specific drug is working but how it is working through protease data.

We can help determine whether the drug is activating at a site of engagement, we can tell mechanisms of action because theres specific protease activity thats associated with that, we can determine through a course of treatment whether the disease is increasing or decreasing, we can track all that through a protease signature, Loew says.

A platform with potential

Through its partnership with Gilead, Glympses technology is expected to move into efficacy trials with NASH patients later this year. The company hopes those trials show the power of its approach for gathering previously unattainable data.

Those insights could also transform treatment. Looking forward, Glympse hopes to help clinicians make care decisions for patients based on both real-time disease response and how the disease has responded in similar patients at similar stages of treatment.

That would represent a paradigm shift in areas like cancer immunotherapy, in which doctors often must make do with little information for months after treatment begins.

Many of these patients have very fast advancing cancers, Loew says. To get the patients quickly stratified to the right treatment is critically important. Days mean everything to these patients, and sometimes we see patients waiting around for nine to 12 weeks to see if theyre having a response to these drugs. In our preclinical data, were determining if theres a response in a week or two. If were able to pull that through, its game-changing.

Read the original:
Faster tracking of treatment responses - MIT News

Read More...

NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer – Business Wire

Wednesday, February 3rd, 2021

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

We believe that NBTXR3 could have a positive impact for patients with cancer in any case where radiotherapy is a part of the standard of care. Expansion into esophageal cancer represents not only another step toward achieving our goals, it also highlights the ongoing progress of our clinical collaboration agreement with The University of Texas MD Anderson Cancer Center. Laurent Levy, CEO of Nanobiotix

NANOBIOTIX (Euronext: NANO NASDAQ: NBTX the Company), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary nanotechnology to transform the treatment of cancer, today announced that the first patient has been injected in a phase I study evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer. The trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) as part of an ongoing clinical collaboration.

Background and Opportunity

According to the World Health Organization, esophageal cancer is currently the sixth most common cause of cancer death in the world and is estimated to have caused over 508,585 deaths in 2018. The American Cancer Society estimates that in 2020 in the United States, there were approximately 18,440 new esophageal cancer cases diagnosed, and approximately 16,170 deaths due to esophageal cancer. Approximately 20% of patients survive esophageal cancer at least five years after diagnosis.

Phase I Study of NBTXR3 Activated by Radiotherapy with Concurrent Chemotherapy for Patients with Esophageal Cancer (MD Anderson Study 2020-0122)

This study is an open-label, single-arm, prospective phase I study consisting of two parts: (i) dose-escalation to determine the RP2D of NBTXR3 activated by radiotherapy with concurrent chemotherapy, and (ii) expansion at RP2D with toxicity monitoring.

The patient population will include adults (age 18 years) with stage II-III adenocarcinoma of the esophagus that are treatment-nave and radiographically non-metastatic at screening. The number of participants enrolled will be determined based on the maximum number required to establish the RP2D of NBTXR3 activated by radiation therapy. Up to 24 subjects will be enrolled, including a maximum of 12 subjects for the dose-escalation part. Twelve additional subjects will be enrolled for the RP2D expansion part. Recruitment is ongoing and the planned enrollment period is 24 months.

Updates on this trial will be provided as they are made available by MD Anderson.

***

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs novel, potentially first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Companys headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

Disclaimer

This press release contains certain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, anticipate, believe, expect, intend, on track, plan, scheduled, and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data, and our relationship with, and the performance of, our collaboration partners, and the funding of our operations. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However, these forward-looking statements are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020 under the caption Risk Factors and those set forth in the universal registration document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.20-010 on May 12, 2020 (a copy of which is available on http://www.nanobiotix.com), as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Read the original post:
NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer - Business Wire

Read More...

New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale – Georgia Tech News Center

Tuesday, January 12th, 2021

Science and Technology

January 11, 2021 Atlanta, GA

Click image to enlarge

Image shows a mass spectrometer and scanning electronic microscope that provide the foundation for the BeamMap system, which can simultaneously determine surface topology and chemical makeup of a biological sample.

A new imaging instrument able to simultaneously study both the surface of a biological sample and its chemical composition is the goal of a three-year, $1.2 million National Institutes of Health (NIH) research award. Combining information from analysis of the chemical composition and physical structure of the surface of cells, tissues and even individual biomolecules inside the cells could provide a new way to study tumor growth, disease progression, cell function, and other key issues.

The technology being developed, termed Beam Enabled Accurate Mapping & Molecular Analyte Profiling (BeamMap), combines data from scanning electron microscopy and a new mode of desorption electrospray ionization mass spectrometry (DESI-MS) to simultaneously determine surface topology and chemical makeup. BeamMap uses an electron beam and a focused nanospray of electrified liquid to gather the two types of information, which is correlated with help of image processing software. The research is funded by the National Institute of Healths National Institute of General Medical Sciences (NIGMS).

To make this breakthrough tool, we need to be able to provide both topological and chemical information at resolutions on the scale of micrometers and sub-micrometers to be able to discover molecular makeup and biological function at a sub-cellular level, said Andrei Fedorov, Professor and Rae S. and Frank H. Neely Chair in the George W. Woodruff School of Mechanical Engineering at the Georgia Institute of Technology. This will require simultaneous advances, and we will be pushing the limits of both imaging tools and what mass spectrometers can do.

Because of the use of mass spectrometry for molecular sensing, BeamMap will be able to characterize proteins, metabolites, and lipid chemistry without requiring an a priori knowledge of what chemical species are present. With its ability to correlate chemical information with topological information acquired with focused electron and ion-spray beams in vacuum, the new instrument is expected to provide an order of magnitude improvement in the resolution of electrospray-based techniques, with chemical imaging resolution of approximately 250 nanometers and electron microscopy topological resolution of about 50 nanometers. BeamMap should be useful in fundamental and clinical biology, medicine, analytical chemistry, and bioengineering.

Processes that are currently invisible to us could actually be seen using BeamMap, so we will have evidence for things we can only speculate about now, Fedorov said. Being able to see what is happening at the subcellular level will allow us to get a better understanding of how biological systems behave. That will allow us to create hypotheses for how cells and tissues interact with the environment, potentially leading to a whole host of new therapeutic applications.

Among the major challenges that require an innovative research approach are the creation of soft ionization and highly local sample extraction necessary for keeping the biomolecules intact and the ability to effectively deliver the charged molecules to the vacuum environment of the mass spectrometer, he said.

We will need to fine-tune the energy of the beam that sprays on the substrate to provide the resolution we need, Fedorov said. We need to extract live biomolecules and ionize them without disrupting their structure. To do this, we will have to use the softest possible ionization.

The instrument will use the electrospray technique to create charged molecules of solvent focused in a beam about 100 nanometers in diameter. As the beam of charged solvent molecules hits the surface of the biological sample, it will ablate molecules from samples surface and move them into the surrounding vacuum environment of the SEM imaging chamber. The molecules will be charged and volatilized by the impinging nano-electrospray at a precisely tuned energy input, and then be extracted for immediate analysis in the mass spectrometer.

In parallel, an electron beam that can be focused down to 10 nanometers will be scanning and profiling the structures and features of the surfaces from which the molecules are being extracted by the electrospray. Correlating data from the two beams will provide information about the chemical makeup of the cell surface, the organelles and intracellular structures being imaged topologically.

Using multiple passes of the two beams will allow removal of layers from the samples, allowing internal structures to be mapped. Fedorov said producing each image will require several minutes, the timing limited by the speed at which the samples can be moved into the mass spectrometer and analyzed.

The characterization will be done in an electron microscope vacuum chamber, with the samples on a stage that can be moved in three dimensions. The stage will also provide cooling and hydration for the living samples during the imaging process.

The idea for the instrument came from a discussion with Andrs Garca, Regents' Professor in the George Woodruff School of Mechanical Engineering and executive director of Georgia Techs Institute for Bioengineering and Bioscience. Garca studies pancreatic cells as part of research into diabetes, and plans to use information from the new technique to develop a better understanding of the disease.

BeamMap is an exciting technological advance that will provide unparalleled biological and chemical information with high spatial resolution to analyze complex biological processes, Garca said. We are very much looking forward to applying it to understand diabetes disease progression.

This research was supported by Award 1R01GM138802-01 from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the NIH.

Research NewsGeorgia Institute of Technology177 North AvenueAtlanta, Georgia 30332-0181 USA

Media Relations Contact: John Toon (404-894-6986) (jtoon@gatech.edu)

Writer: John Toon

See the original post here:
New Instrument Will Uncover Structure and Chemical Composition on Sub-Cell Scale - Georgia Tech News Center

Read More...

Page 11234..10..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick